Part B Open-Label Extension ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
51	全身性強皮症	1

51. 全身性強皮症

---

臨床試験数 : 525 /  薬物数 : 565 - (DrugBank : 148) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 217

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02465437 (ClinicalTrials.gov)	August 2015	4/6/2015	Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis	A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Diffuse Cutaneous Systemic Sclerosis	Diffuse Cutaneous Systemic Sclerosis	Drug: JBT-101;Drug: Placebo;Drug: Part B Open-Label Extension	Corbus Pharmaceuticals Inc.	NULL	Active, not recruiting	18 Years	70 Years	All	42	Phase 2	United States